Our Estimates and Your Savings


Oakmontscript’s model-based estimates of biosimilars have given our partners an edge over their competitors in gaining more market shares. We would review at least 150 sources before offering cost saving estimates to our clients. The magnitude of savings from us is determined by a correct estimation of the assumptions on biosimilar price relative to the originator price---that is 27%, while the general biosimilar market share assumptions averages at 28 percent. Many distributors from outside the US are very inexperienced in the purchase of biosimilars; their key assumptions on market share and biosimilar prices are “best guesses” based on anecdotes or professionals’ opinions, when our estimates are more reliable and more rewarding when it comes to cutting down total biologic spending and gaining a bigger share in the market of biosimilars.

big data-3 - Copy.png